A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.

Autor: Meyer J; From the Meridan Clinical Research, Lincoln, Nebraska., Silas P; Wee Care Pediatrics, Syracuse, Utah., Ouedraogo GL; Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania., McElwee K; Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania., Keep G; Vaccine Research and Development, Pfizer UK, Hurley, UK., Trammel J; Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania., Peng Y; Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania., Scully IL; Vaccine Research and Development, Pfizer Inc, Pearl River, New York., Gruber WC; Vaccine Research and Development, Pfizer Inc, Pearl River, New York., Scott DA; Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania., Watson W; Vaccine Research and Development, Pfizer Inc, Collegeville, Pennsylvania.

Publikováno v: The Pediatric infectious disease journal [Pediatr Infect Dis J] 2024 Jun 01; Vol. 43 (6), pp. 574-581. Date of Electronic Publication: 2024 Mar 15.

Use of pre-ART laboratory screening to identify renal, hepatic and haematological abnormalities in Côte d'Ivoire.

Autor: Minchella PA; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA., Adjé-Touré C; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire., Zhang G; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA., Tehe A; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire., Hedje J; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire., Rottinghaus ER; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, GA, USA., Natacha K; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire., Diallo K; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Pretoria, South Africa., Ouedraogo GL; Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire., Nkengasong JN; Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.

Publikováno v: Tropical medicine & international health : TM & IH [Trop Med Int Health] 2020 Apr; Vol. 25 (4), pp. 408-413. Date of Electronic Publication: 2020 Jan 20.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

Autor: Pantaleo G; Service of Immunology and Allergy, and Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: giuseppe.pantaleo@chuv.ch., Janes H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Karuna S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Grant S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Ouedraogo GL; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA; US Centers for Disease Control and Prevention, Atlanta, GA, USA., Allen M; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Tomaras GD; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Frahm N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA., Montefiori DC; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Ferrari G; Department of Surgery, Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA., Ding S; EuroVacc Foundation, Lausanne, Switzerland., Lee C; Global Solutions for Infectious Diseases, South San Francisco, CA, USA., Robb ML; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA., Esteban M; Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Madrid, Spain., Wagner R; Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany., Bart PA; Service of Immunology and Allergy, and Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland., Rettby N; Service of Immunology and Allergy, and Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Publikováno v: The lancet. HIV [Lancet HIV] 2019 Nov; Vol. 6 (11), pp. e737-e749. Date of Electronic Publication: 2019 Oct 07.

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

Autor: Moodie, Zoe¹ (AUTHOR) zoe@fredhutch.org, Andersen-Nissen, Erica^1,2 (AUTHOR), Grunenberg, Nicole¹ (AUTHOR), Dintwe, One B.^1,2 (AUTHOR), Omar, Faatima Laher² (AUTHOR), Kee, Jia J.¹ (AUTHOR), Bekker, Linda-Gail³ (AUTHOR), Laher, Fatima⁴ (AUTHOR), Naicker, Nivashnee⁵ (AUTHOR), Jani, Ilesh⁶ (AUTHOR), Mgodi, Nyaradzo M.⁷ (AUTHOR), Hunidzarira, Portia⁷ (AUTHOR), Sebe, Modulakgota⁸ (AUTHOR), Miner, Maurine D.¹ (AUTHOR), Polakowski, Laura⁹ (AUTHOR), Ramirez, Shelly¹ (AUTHOR), Nebergall, Michelle¹ (AUTHOR), Takuva, Simbarashe¹ (AUTHOR), Sikhosana, Lerato¹⁰ (AUTHOR), Heptinstall, Jack¹¹ (AUTHOR)

Publikováno v: PLoS Medicine. 3/19/2024, Vol. 21 Issue 3, p1-23. 23p.

d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS.

Autor: Porter BO; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Ouedraogo GL, Hodge JN, Smith MA, Pau A, Roby G, Kwan R, Bishop RJ, Rehm C, Mican J, Sereti I

Publikováno v: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2010 Jul; Vol. 136 (1), pp. 42-50. Date of Electronic Publication: 2010 Mar 15.